ライフサイエンスコーパス: PVI

1 PVI alone was performed in 23 of 85 (27%) patients of gr

2 PVI offers limited value to OSA patients not treated wit

3 PVI only seems to be sufficient to treat patients with l

4 PVI treatment enhanced wound healing via promotion of ex

5 PVI was performed using circular mapping (CM) alone (gro

6 PVI+CFAE ablation versus PVI alone did not improve the o

7 PVI+GP ablation strategy compared with PVI alone yielded

8 tive on 22 226 patients who underwent 27 048 PVI from August 2007 to May 2013.

9 Overall, 21+/-4 months after 1 PVI session, the sinus rhythm maintenance rate without a

10 Subjects were randomized as follows: arm 1, PVI + ablation of non-PV triggers identified using a sti

11 nfusion (PVI) 225 mg/m2/d during XRT; arm 2 (PVI-only arm), with PVI 42 days before and 56 days after

12 olymer [Os(4,4'-dimethyl-2,2'-bipyridine)(2)(PVI)Cl](+) had a potential of +309 mV versus NHE, and th

13 Atrial tachyarrhythmias recurred in 28 PVI-only group patients and 24 Substrate-modification gr

14 It has been found that 0.5% PVI can attenuate congestion, edema and pain induced by

15 e data show that topical application of 0.5% PVI could promote acute skin wound healing though increa

16 other two were dressed with gauze with 0.5% PVI for 1 hour per day for the first 5 days after injury

17 431542 and all wounds were treated with 0.5% PVI for 5 days.

18 is study aimed to assess the effects of 0.5% PVI on acute skin wounds.

19 Continuous electric activity ablation+PVI result in a similar incidence of acute AF terminatio

20 cantly lower using generalized CFAE ablation+PVI.

21 predicted arrhythmia recurrences, and acute PVI responders had a reduced risk of relapse (hazard rat

22 itional ablation was performed only in acute PVI nonresponder, if direct current cardioversion failed

23 Acutely, PVI was achieved in 36 of 40 PVs (90%).

24 In patients with recurrent AF after PVI, return of PV conduction can be expected.

25 as (AT) in patients with persistent AF after PVI.

26 eral factors independently predict ASC after PVI.

27 lore the risk of cardiovascular events after PVI in patients with and without guideline-recommended a

28 if direct current cardioversion failed after PVI.

29 y at baseline, in the left atrium (LA) after PVI and linear lesions (roof and mitral isthmus), and bi

30 fibrillation substrate, linear lesions after PVI diminished the target area for CFE ablation, and com

31 rate of electric reconduction 3 months after PVI is high in patients with initially isolated PVs.

32 nce of >/=142 PACs per day at 6 months after PVI was independently associated with a significantly in

33 epeat electrophysiology study 2 months after PVI, regardless of symptoms, to document the number of r

34 ignificantly improved patient outcomes after PVI.

35 ions, defined as CFE area, was reduced after PVI (18.3+/-12.03 to 10.2+/-7.1 cm(2); P<0.001) and agai

36 Elimination of extra-PV AF sources after PVI is superior to sole PV isolation with the adjunct of

37 re, identify factors predicting stroke after PVI, and explore the risk of cardiovascular events after

38 iscontinuing anticoagulation treatment after PVI in association with the CHA2DS2-VASc (congestive hea

39 discontinuation of warfarin treatment after PVI is not safe in high-risk patients, especially those

40 lationship between ERAT beyond 4 weeks after PVI and postblanking AT recurrence merits further invest

41 ERAT occurring beyond 4 weeks after PVI is associated with PVrc and particularly of PVrc of

42 zed that ERAT occurring beyond 4 weeks after PVI is associated with PVrc at repeat electrophysiology

43 ta-blockers, were discontinued 4 weeks after PVI.

44 were followed up for more than 1 year after PVI.

45 ive strategies comprising either stand-alone PVI (PVI-only approach) or a stepwise approach of PVI fo

46 en an index ablative approach of stand-alone PVI and a stepwise approach of PVI plus complex fraction

47 Patients were randomized 1:1 to stand-alone PVI or PVI plus substrate modification.

48 edural outcomes (procedure, fluoroscopy, and PVI times) were comparable between the 3 arms.

49 +/- 5 min, and 23 +/- 5 min for PVI, GP, and PVI+GP groups, respectively (p < 0.001).

50 ), and 61 (74%) patients in the PVI, GP, and PVI+GP groups, respectively (p = 0.004 by log-rank test)

51 ith planned doses of radiation (59.4 Gy) and PVI of 5-FU (200 mg/m(2)/d) with gemcitabine doses of 50

52 ssed the safety and effectiveness of LEB and PVI in patients with symptomatic claudication and critic

53 nts with discrepancies between CAC score and PVI rank quartiles had a higher percentage of soft and f

54 atabases for studies on ostial versus antral PVI.

55 ostial isolation of the PVs and wide antral PVI.

56 In group B, PVI was performed with the patient either in spontaneous

57 nt second-generation 28-mm cryoballoon-based PVI in 2 centers (St. George's hospital and Harburg hosp

58 ul second-generation 28-mm cryoballoon-based PVI were included in this analysis.

59 ted] Dabigatran was held 1 to 2 doses before PVI and restarted at the conclusion of the procedure or

60 This suggests that a screening TEE before PVI should be performed in patients with a CHADS(2) scor

61 hat additional substrate modification beyond PVI does not improve single-procedure efficacy in patien

62 rtium Peripheral Vascular Intervention (BMC2 PVI) database, we identified 1357 peripheral vascular in

63 s electric activity were ablated followed by PVI.

64 Circumferential PVI using irrigated radiofrequency current was performed

65 nd randomized as follows: 1) circumferential PVI (n = 78); 2) anatomic ablation of the main left atri

66 ft atrial GP (n = 82); or 3) circumferential PVI followed by anatomic ablation of the main left atria

67 trogram-based ablation after circumferential PVI isolation.

68 m effects meta-analysis of studies comparing PVI versus PVI+CFAE ablation.

69 ablation line, whereas in group B, complete PVI without any gaps was intended.

70 .001), for a difference in favor of complete PVI of 17.1% (95% confidence interval, 5.3%-28.9%).

71 his study proves the superiority of complete PVI over incomplete PVI with respect to AF recurrence wi

72 d to either incomplete (group A) or complete PVI (group B).

73 Shield of Michigan Cardiovascular Consortium PVI registry.

74 Conventional PVI transects the major left atrial GP, and it is possib

75 n to PVI is more effective than conventional PVI-only strategy for persistent AF.

76 To date, PVI has been performed primarily in patients with normal

77 schizophrenia and autism spectrum disorder, PVI circuits are altered in these psychiatric disorders.

78 When "wired" with Os(dmbpy)PVI, the graphite electrodes modified with fdgPDH showed

79 ne)2(poly(vinylimidazole))10Cl](+) [Os(dmbpy)PVI] and [Os(4,4'-dimethoxy-2,2'-bipyridine)2(poly-(viny

80 )2(poly-(vinylimidazole))10Cl](+) [Os(dmobpy)PVI].

81 C within 60 s independently predict durable PVI.

82 Termination of AF during PVI was observed in 31 (65%) patients, whereas AF persis

83 ents were prospectively randomized to either PVI alone (n = 78) or full defrag (n = 75), with 52 pati

84 tly higher success rate compared with either PVI or GP alone in patients with PAF.

85 rrhythmic drugs or repeat ablation following PVI (65.6% vs. 33.3%; p = 0.02).

86 AF recurrence following PVI in CPAP nonuser patients was significantly higher (H

87 SA is a predictor of AF recurrence following PVI.

88 CFE area was progressively reduced following PVI and linear lesions, and LA ablation reduced right at

89 Interleukin 6 was reduced following PVI treatment.

90 For PVI, all 4 PV antra were isolated with confirmed entranc

91 et lesion revascularization were greater for PVI than for LEB in patients presenting with claudicatio

92 /- 3 min, 20 +/- 5 min, and 23 +/- 5 min for PVI, GP, and PVI+GP groups, respectively (p < 0.001).

93 pping catheter were used in all patients for PVI.

94 Currently, 2 main approaches are used for PVI: ostial isolation of the PVs and wide antral PVI.

95 specific molecular divergence of hippocampal PVI subtypes, suggesting that activation of GABA(B)Rs ma

96 groups: 5.1% in PVI, 4.9% in GP, and 6.1% in PVI+GP.

97 utter did not differ between groups: 5.1% in PVI, 4.9% in GP, and 6.1% in PVI+GP.

98 in for the periprocedural anticoagulation in PVI.

99 superiority of complete PVI over incomplete PVI with respect to AF recurrence within 3 months.

100 in isolation (PVI) is superior to incomplete PVI with regard to the patients' clinical outcome.

101 During the index PVI, the standard freeze cycle duration was 240 s.

102 The coronary plaque volume index (PVI) was determined by dividing the wall volume by the c

103 n entries over time (pain variability index [PVI]).

104 or fetal periventricular venous infarction (PVI) were recruited.

105 XRT) plus FU via protracted venous infusion (PVI) 225 mg/m2/d during XRT; arm 2 (PVI-only arm), with

106 phase I trial of protracted venous infusion (PVI) fluorouracil (5-FU) plus weekly gemcitabine with co

107 e the outcome of protracted venous infusion (PVI) fluorouracil (FU) with standard weekly cisplatin an

108 lthough the AF recurrence rate after initial PVI in impaired EF patients was higher than in normal EF

109 After initial PVI, 73% of patients with impaired EF and 87% of patient

110 Peripheral vascular intervention (PVI) is an effective treatment option for patients with

111 related to peripheral vascular intervention (PVI) procedures.

112 cations of peripheral vascular intervention (PVI); however, their incidence and risk factors remain u

113 Povidone-iodine (PVI) is principally used as an antimicrobial agent.

114 ic nerve, and esophagus during PV isolation (PVI) using the second-generation cryoballoon are not kno

115 y achievement while performing PV isolation (PVI).

116 e survival between pulmonary vein isolation (PVI) and a stepwise approach (full defrag) consisting of

117 in achieving acute pulmonary vein isolation (PVI) and favorable clinical outcome.

118 nking period after pulmonary vein isolation (PVI) as early recurrence of atrial tachyarrhythmia (ERAT

119 F) may recur after pulmonary vein isolation (PVI) as the result of either recurrent PV conduction or

120 delivers effective pulmonary vein isolation (PVI) associated with superior 1-year clinical outcome.

121 involving not only pulmonary vein isolation (PVI) but also additional linear lesions and ablation of

122 on of conventional pulmonary vein isolation (PVI) by circumferential antral ablation with ganglionate

123 Pulmonary vein isolation (PVI) for atrial fibrillation is associated with a transi

124 Pulmonary vein isolation (PVI) for persistent atrial fibrillation is associated wi

125 atients undergoing pulmonary vein isolation (PVI) for treatment of atrial fibrillation (AF).

126 t decade, electric pulmonary vein isolation (PVI) has become a procedure implemented worldwide for th

127 ty and efficacy of pulmonary vein isolation (PVI) in atrial fibrillation (AF) patients with impaired

128 ion in addition to pulmonary vein isolation (PVI) in patients undergoing ablation for AF.

129 Pulmonary vein isolation (PVI) is a recommended treatment for patients with atrial

130 cedure efficacy of pulmonary vein isolation (PVI) is less than optimal in patients with persistent at

131 Pulmonary vein isolation (PVI) is still associated with a substantial number of ar

132 n whether complete pulmonary vein isolation (PVI) is superior to incomplete PVI with regard to the pa

133 durability of the pulmonary vein isolation (PVI) lines, but also the pathophysiological understandin

134 hypothesized that pulmonary vein isolation (PVI) plus ablation of selective atrial low-voltage sites

135 pite the fact that pulmonary vein isolation (PVI) should be performed prophylactically for all pulmon

136 blated followed by pulmonary vein isolation (PVI).

137 a (OSA) undergoing pulmonary vein isolation (PVI).

138 ce is common after pulmonary vein isolation (PVI).

139 as circumferential pulmonary vein isolation (PVI).

140 were referred for pulmonary vein isolation (PVI).

141 ogram (TEE) before pulmonary vein isolation (PVI); and 2) the relationship of a CHADS(2) score with l

142 urther applications to ensure a long-lasting PVI.

143 % female) who underwent lower extremity (LE)-PVI from 2004 to 2009 at 16 hospitals participating in t

144 ificant proportion of patients undergoing LE-PVI, have a more severe and complex disease process, and

145 eral artery disease, in comparison with LEB, PVI was associated with fewer 30-day procedural complica

146 procedural success compared with men, making PVI an effective treatment strategy among women with LE-

147 curred in 1 (1%) patient 2 days after manual PVI.

148 In 1 patient undergoing manual PVI (1%), an SCL with asymptomatic subarachnoid hemorrha

149 similar after RA-PVI as compared with manual PVI.

150 n isolation (RA-PVI) as compared with manual PVI.

151 derwent high-density atrial voltage mapping, PVI, and ablation at low-voltage areas (LVA < 0.5 mV in

152 The mean PVI (+/-standard deviation) was 11.2 mm(2) +/- 2.7.

153 PVI-only approach) or a stepwise approach of PVI followed by complex fractionated atrial electrogram

154 f stand-alone PVI and a stepwise approach of PVI plus complex fractionated atrial electrogram and lin

155 The procedure in group A consisted of PVI exclusively.

156 tepwise approach (full defrag) consisting of PVI, ablation of complex fractionated electrograms, and

157 n schizophrenia, we show that dysfunction of PVI signaling in the PFC specifically produces deficits

158 hibition of TGF beta abolished the effect of PVI treatment on wound closure.

159 tion plays a central role in the efficacy of PVI.

160 The outcomes of PVI in patients with impaired LV systolic function are u

161 The rate of PVI declined in inpatient settings from 209.7 to 151.6 (

162 The annual rate of PVI increased slightly from 401.4 to 419.6 per 100,000 M

163 , we examined age- and sex-adjusted rates of PVI by year, type of procedure, clinical setting, and ph

164 From 2006 to 2011, overall rates of PVI increased minimally.

165 e trends in the use and clinical settings of PVI and the effect of changes in reimbursement.

166 procedures were similar across all types of PVI, whereas mean costs of atherectomy procedures in out

167 o encourage more efficient outpatient use of PVI in the United States.

168 were performed for </=2 deliveries based on PVI without a bonus freeze.

169 ABA(B)Rs was also present at lower levels on PVI axon terminals.

170 However, the impact of CPAP therapy on PVI outcome in patients with OSA is poorly known.

171 ting patients were randomized to PVI only or PVI with renal artery denervation.

172 ts were randomized 1:1 to stand-alone PVI or PVI plus substrate modification.

173 ized due to AF termination with the original PVI.

174 ntral approach is more effective than ostial PVI in achieving freedom from total atrial tachyarrhythm

175 not seem to provide additional benefit over PVI alone in patients with persistent AF, but it is asso

176 ith bilirubin oxidase (BOD) "wired" with PAA-PVI-[Os(4,4'-dichloro-2,2'-bipyridine)(2)Cl](+/2+) (poly

177 In 105 patients, PVI was the sole ablative therapy, 49 (46.7%) of those p

178 Percutaneous PVI is frequently performed for the treatment of periphe

179 Persistent PVI could be documented in 90 of 115 PVs (78.2%).

180 is associated with a high rate of persistent PVI.

181 eevaluation to assess the rate of persistent PVI.

182 ) which is modified with polyvinylimidazole (PVI).

183 ts at increased risk of ASC may improve post-PVI outcomes.

184 clinical implications for the design of post-PVI follow-up.

185 hrombus in patients with AF undergoing a pre-PVI screening TEE is very low (<2%) and increases signif

186 Initial TEEs for pre-PVI of 1,058 AF patients (age 57 +/- 11 years, 80% men)

187 >75 years, female sex, white race, no prior PVI, nonfemoral arterial access site, >6-Fr sheath size,

188 atrial fibrillation ablation by prophylactic PVI along with SVCI was almost the same as with the conv

189 trategies comprising either stand-alone PVI (PVI-only approach) or a stepwise approach of PVI followe

190 d size of SCL appears to be similar after RA-PVI as compared with manual PVI.

191 ically assisted pulmonary vein isolation (RA-PVI) as compared with manual PVI.

192 f SCLs was similar in patients undergoing RA-PVI as compared with manually ablated patients (n=9, 18%

193 Fifty patients underwent RA-PVI and 20 patients underwent a manual approach.

194 However, after changes in reimbursement, PVI and atherectomy in outpatient facilities and office-

195 Repeat PVI provides significant clinical benefit for these pati

196 conduction in 51 PVs (15 patients) at repeat PVI.

197 e undergoing PVI only and patients requiring PVI+selective low-voltage ablation (P = 0.42).

198 ompared to a group of patients from the same PVI cohort without OSA.

199 pain variability were observed (mean +/- SD PVI 1.61 +/- 0.656 [range 0.27-4.05]).

200 antly lower in wide antral than in segmental PVI group (odds ratio, 0.42; 95% confidence interval, 0.

201 etiological aspects of these disorders show PVI deficits to be all accompanied by oxidative stress i

202 In this study, PVI FU does not show improved outcome over weekly cispla

203 After successful PVI, a bonus freeze cycle of 240 s was applied in the fi

204 his information may be useful for successful PVI without severe complications.

205 with recurrent AF after initially successful PVI and the clinical outcome after a repeat procedure.

206 size was nonrandomized, our results suggest PVI may be a feasible therapeutic option in AF patients

207 procedure, yields higher success rates than PVI or GP ablation alone, in patients with paroxysmal at

208 ow-voltage sites may be more successful than PVI only.

209 ned interim futility analysis indicated that PVI FU/RT had a higher treatment failure rate (35% highe

210 Our primary finding is that PVI performed with a wide antral approach is more effect

211 The PVI FU/RT arm continues to show a higher risk of treatme

212 The PVI was related to age (standardized beta = 0.32, P < .0

213 The use of pacing to ensure UE along the PVI line markedly improved near-term single-procedure su

214 The relationship between the PVI and cardiovascular risk factors was determined with

215 9% to 55% of the bolus arms versus 4% in the PVI arm.

216 in the failure rate at distant sites in the PVI FU arm.

217 enervation without significant change in the PVI only group.

218 56%), 39 (48%), and 61 (74%) patients in the PVI, GP, and PVI+GP groups, respectively (p = 0.004 by l

219 ablations were performed (mean: 1.59 in the PVI-alone group, 1.55 in the full-defrag group).

220 4% (95% confidence interval, 43%-68%) in the PVI-only and 57% (95% confidence interval, 46%-72%) in t

221 Twenty-four patients in the PVI-only group (39%) and 18 in the Substrate-modificatio

222 ion versus 4 (29%) of the 14 patients in the PVI-only group (p = 0.033).

223 patients included in the analysis (61 in the PVI-only group, 57 in the Substrate-modification group).

224 rite-ion was investigated by using CV on the PVI modified CPE.

225 diography improves the outcome of cooled-tip PVI.

226 Addition of GP ablation to PVI confers a significantly higher success rate compared

227 within/at borderzones of LVA in addition to PVI is more effective than conventional PVI-only strateg

228 The role of CFAE ablation in addition to PVI should be questioned and other alternatives assessed

229 Selective atrial ablation in addition to PVI was performed in 62 patients with termination of AF

230 in all cases prophylactically in addition to PVI.

231 s a common pathological mechanism leading to PVI impairment in schizophrenia and some forms of autism

232 Consenting patients were randomized to PVI only or PVI with renal artery denervation.

233 nts were enrolled, and 14 were randomized to PVI only, and 13 were randomized to PVI with renal arter

234 mized to PVI only, and 13 were randomized to PVI with renal artery denervation.

235 own about sex-related differences related to PVI procedures.

236 CFE (mean cycle length </=120 ms) remote to PVI and linear lesions, defined as CFE area, was reduced

237 At receiver-operator curve analysis, time to PVI <60 s identified the absence of PV reconduction (sen

238 In the multivariable analysis, time to PVI (P=0.03) and failure to achieve -40 degrees C within

239 In addition, 60-s cut-off for time to PVI indicates persistent isolation with 96.4% negative p

240 h paroxysmal atrial fibrillation who undergo PVI and leads to a substantial midterm sinus rhythm main

241 patients with atrial fibrillation undergoing PVI from the Swedish Catheter Ablation Register were inc

242 systems, we compared 883 patients undergoing PVI and 975 patients undergoing LEB between January 1, 2

243 included 377 consecutive patients undergoing PVI between December 2000 and January 2003.

244 dural anticoagulation in patients undergoing PVI compared with uninterrupted warfarin therapy.

245 important therapy in OSA patients undergoing PVI that improves arrhythmia free survival.

246 total of 999 consecutive patients undergoing PVI were included; 376 patients were on dabigatran (150

247 Among 185 patients undergoing PVI, 52 reported no significant improvement in their cli

248 ith a control group (66 patients) undergoing PVI only (group II).

249 with a low amount of low voltage undergoing PVI only and patients requiring PVI+selective low-voltag

250 Identifying mechanism(s) underlying PVI deficits is essential to establish treatments target

251 Twenty dogs underwent PVI using second-generation cryoballoon.

252 ith paroxysmal atrial fibrillation underwent PVI using Carto and Lasso.

253 Three hundred fifteen patients underwent PVI for treatment of AF.

254 years old, 40 men), who previously underwent PVI following the standard approach of our institution,

255 Among 426 patients who underwent PVI between 2007 and 2010, 62 patients had a polysomnogr

256 PVI+CFAE ablation versus PVI alone did not improve the overall rate of freedom fr

257 eta-analysis of studies comparing PVI versus PVI+CFAE ablation.

258 latin 40 mg/m2, and experimental therapy was PVI FU 225 mg/m2/d for 5 d/wk for six cycles during RT.

259 tudied: 46 with NAIS, 34 with APPIS, 55 with PVI, and 77 controls (male, 53%; median age, 4.8 years).

260 /m2/d during XRT; arm 2 (PVI-only arm), with PVI 42 days before and 56 days after XRT + PVI; or arm 3

261 nd reduces AF recurrences when combined with PVI.

262 PVI+GP ablation strategy compared with PVI alone yielded a hazard ratio of 0.53 (95% confidence

263 However, in comparison with PVI, LEB was associated with increased rates of complica

264 gemcitabine into regimens of radiation with PVI 5-FU.

265 If AF did not terminate with PVI, ablation was continued by targeting extra-PV AF sou

266 Nine of the 13 patients (69%) treated with PVI with renal denervation were AF-free at the 12-month

267 .001) were observed in patients treated with PVI with renal denervation without significant change in

268 h PVI 42 days before and 56 days after XRT + PVI; or arm 3 (bolus-only arm), with bolus FU + leucovor